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Purpose: Several strategies of prostate biopsy (PBx) have been introduced to improve prostate cancer (PCa) detection rates. How-
ever, studies comparing cancer detection rates (CDRs) according to biopsy methods in real-world practice are scarce. This study 
aimed to investigate CDRs according to the biopsy methods for patients with prostate-specific antigen (PSA) <10.0 ng/mL.
Materials and Methods: From 2006 to 2015, patients who underwent PBx were initially selected. All patients were categorized ac-
cording to the biopsy methods performed (magnetic resonance imaging targeted biopsy [MR-TBx], 12+2 hypoechoic lesion target 
biopsy, saturation biopsy [sPBx], extended biopsy, and 12-core PBx). The CDR of MR-TBx was compared to that of sPBx and other 
protocols. Volume per core (VPC) was defined as prostate volume divided by the number of biopsy cores. Patients previously diag-
nosed with PCa were excluded.
Results: Of the 1,598 patients (median PSA, 5.41 ng/mL), 401 (25.1%) were diagnosed with PCa. Among the biopsy methods, MR-
TBx has the highest CDR and proportion of Gleason score ≥7 (3+4). Biopsy methods, VPC, age, prostate volume, and PSA were as-
sociated with PCa detection. In the sub-analysis for initial biopsy, MR-TBx had no significant difference with sPBx, but had higher 
CDR than the other biopsy protocols. For repeat biopsy, VPC, rather than the biopsy method, was associated with CDR.
Conclusions: This study reaffirmed the efficacy of MR-TBx on CDR in real-world practice. In cases with barriers to performing mag-
netic resonance imaging, VPC might be useful for adjusting the optimal number of biopsy cores in repeat biopsy.
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INTRODUCTION
Since the 6-core biopsy was introduced by Hodge et al. 
[1], the 10- to 12-core transrectal ultrasound (TRUS)-guided 
biopsy has become the standard diagnostic method [2]. To 
improve the efficacy of prostate biopsy (PBx), several biopsy 
methods, including saturation biopsy, extended biopsy, and 
advanced technology, such as multi-parametric magnetic 
resonance imaging (MRI), contrast-enhanced TRUS, and so-
no-elastography, were widely introduced [3,4]. Regarding bio-
markers, percent-free prostate-specific antigen (PSA), pros-
tate health index (PHI®; Beckman Coulter, Brea, CA, USA), 
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ExoDx® prostate intelliscore (EPI; Exosome Diagnostics, Bos-
ton, MA, USA), prostate cancer antigen 3 (PCA3; Progensa, 
Bedford, MA, USA), and so on have been investigated for 
patients with high PSA [5]. Especially, the National Compre-
hensive Cancer Network (NCCN) recommended to consider 
performing MRI or assessing biomarkers before PBx in sus-
picious prostate cancer (PCa) patients [6]. However, because 
of the additional costs, MRI or biomarkers might be only 
used for selected patients.
The increasing number of biopsy cores was generally 
considered to be used to facilitate higher cancer detection 
rate (CDR) in practice. To introduce the newly advanced 
biopsy technique, the outcomes in real-world practice, includ-
ing the CDR, cost-efficacy, and risk of complication, were 
investigated. Furthermore, the outcomes of the advanced 
biopsy technique in real-world practice should be confirmed 
to be superior to those of the increasing number of biopsy 
cores. Although numerous papers have presented the results 
of experts, there are few studies that have analyzed CDRs 
according to the various biopsy methods in practice. There-
fore, the aim of this study was to compare the CDRs of sev-
eral biopsy methods for patients with PSA <10.0 ng/mL.
MATERIALS AND METHODS
1. Study population and data collection
Gangnam Severance Hospital Institutional Review 
Board approval was obtained for this study to collect data 
on all patients who had undergone PBx for suspicious PCa 
at our institution between January 2006 and December 2015 
(approval number: 2019-0325-001), and informed consent was 
obtained from all individual participants included in the 
study. We reviewed 1,631 patients with PSA <10.0 ng/mL. 
A total of 33 biopsies were excluded from the study for the 
following reasons: 16 had received a prior diagnosis of PCa, 
7 had received radiation treatment, 6 had underwent digit-
guided PBx, and 4 were submitted for evaluation for extra-
peritoneal mass. Finally, 1,598 patients were included in the 
final analysis.
Patient characteristics included clinico-pathologic data, 
such as age at PBx, presence of  previous biopsy history, 
prostate volume (PV), PSA, PSA density (PSA value divided 
by PV), volume per core (VPC: PV divided by the number of 
biopsy cores), and biopsy methods [7]. For calculating VPC, 
we hypothesized that the PBx cores were evenly inserted 
into the prostate tissue.
2. Indication and protocols of PBx
The indications for PBx were persistent clinical suspi-
cions of PCa such as elevated PSA level ≥3.0 ng/mL, steadily 
increasing PSA levels, abnormal digital rectal examination, 
abnormal TRUS result, and abnormal pathologic finding 
including high-grade prostatic intraepithelial neoplasia or 
atypical small acinar proliferation of prostate with the prior 
PBx. We performed a PBx under local anesthesia with the 
BK Medical Flex Focus 500 ultrasound system (Analogic 
Corporation, Peabody, MA, USA) by using a 7.5 to 12 MHz 
multiplanar probe.
3. Stratifying biopsy methods
The standard biopsy methods for patients with suspi-
cious PCa was 12-core PBx. To reduce the number of cases 
with unfortunately missed diagnosis of PCa, our institution 
introduced the prebiopsy MRI and several methods related 
to the increasing number of biopsy cores. Our target biopsy 
protocol for MRI targeted biopsy (MR-TBx) or hypoechoic 
lesion on TRUS consisted of 12-core PBx after target biopsy 
on suspicious lesions. MR-TBx with cognitive technique was 
performed by two urologists (L.K.S. or L.D.H). A 12+2 hy-
poechoic lesion target biopsy (12+2HLTBx) was performed 
to evaluate the efficacy of  hypoechoic lesions chosen by 
clinicians experienced in performing MR-TBx for cancer 
detection [8]. Patients who underwent additional biopsy cores 
on lesions with abnormal finding in TRUS were regarded 
as the extended biopsy group. Finally, biopsy methods were 
categorized into 5 groups (MR-TBx, 12+2HLTBx, 24-core 
saturation biopsy (sPBx), extended biopsy, and 12-core PBx). 
However, 12+2HLTBx was not considered as the generalized 
methods. To analyze the efficacy of MR-TBx, we compared 
the CDRs among MR-TBx, sPBx, and other protocols with 
the possibility to improve the CDR in practice (12+2HLTBx, 
extended biopsy, and 12-core PBx).
4. MRI protocol and image analysis
For MR-TBx, all patients underwent imaging using a 3.0T 
MRI system (Intera Achieva 3.0T; Phillips Medical System, 
Best, The Netherlands) equipped with a phased array coil (6 
channels). All patients underwent diffusion weighted imag-
ing MRI and dynamic contrast enhanced MRI in addition 
to the routine prostate MRI protocol of 3 orthogonal planes 
(axial, sagittal, and coronal) used at our institution. Two b 
values (0, 1,000) were used, and diffusion restriction was 
quantified through apparent diffusion coefficient mapping. 
All images were reviewed by 2 experienced uro-radiologists 
who were blinded to the biopsy results. 
5. Statistical analysis




standard deviation). Categorical variables were reported 
as the number of  occurrences and frequency. The Pear-
son’s chi-squared test was used for statistical comparisons 
of  continuous and categorical variables. Univariate and 
multivariate logistic regression analyses were carried out 
using clinical parameters. Variables that were found to be 
significant in the univariate analyses (p<0.05) were entered 
into the multivariate analysis. Receiver operating char-
acteristic (ROC) curves and area under the ROC curves 
(AUCs) were used to obtain the cut-off value. The optimal 
cut-off value of VPC was determined using Youden’s index 
(sensitivity+specificity-1). The optimal cut-off values were 
based on predefined values and according to a sensitivity 
analysis using Youden index. Statistical analyses were per-
formed using the IBM SPSS Statistics version 23.0 for Win-
dows (IBM Corp., Armonk, NY, USA). All tests were two-
sided and performed at the 5% significance level.
RESULTS
The patient characteristics are shown in Table 1. Of the 
1,598 patients, 401 (25.1%) were diagnosed with PCa. The 
mean age of the groups with and without PCa were 66.8 
and 63.3 years, respectively (p<0.001). The group diagnosed 
with PCa had higher PSA level and PSA density, as well as 
lower PV and VPC than that without PCa (p<0.001, p=0.001, 
p<0.001, p<0.001, respectively). Stratifying according to biopsy 
methods, MR-TBx was performed in 73 (4.6%), 12+2HLTBx 
in 120 (7.5%), sPBx in 75 (4.7%), extended biopsy in 212 (13.3%), 
and 12-core PBx in 1,118 (70.0%) cases. The CDRs of MR-TBx, 
12+2HLTBx, sPBx, extended biopsy, and 12-core PBx were 
43.8%, 40.8%, 34.7%, 33.0%, and 20.0%, respectively. There was 
a significant difference in CDRs among the biopsy methods 
(p<0.001). When comparing the characteristics according to 
the biopsy methods, significant differences were found in 
age, hypertension, body mass index, PSA, presence of biopsy 
history, VPC, number of total core, number of positive core, 
and the proportion of  Gleason score ≥7 (3+4) among the 
biopsy methods (p=0.025, p=0.028, p=0.018, p=0.031, p<0.001, 
p<0.001, p<0.001, p<0.001, p=0.037 respectively). In patients 
diagnosed with PCa, the ratios of positive core and total core 
for MR-TBx, 12+2HLTBx, sPBx, extended biopsy, and 12-core 
PBx were 35.7%, 24.6%, 27.6%, 30.2%, and 30.7%, respectively. 
Among the patients diagnosed with PCa, the proportions 
of Gleason score ≥7 (3+4) in MR-TBx, 12+2HLTBx, sPBx, 
extended biopsy, and 12-core PBx were 71.9%, 51.0%, 57.7%, 
65.7%, and 49.6%, respectively.
For predicting the diagnosis of PCa, age (odds ratio [OR], 
1.07; 95% confidence interval [CI], 1.051–1.094; p<0.001), PSA 
(OR, 1.17; 95% CI, 1.078–1.269; p<0.001), PV (OR, 0.97; 95% CI, 
Table 1. Basic patients’ characteristics
Characteristic MR-TBx 12+2HLTBx Saturation biopsy Extended biopsy 12-core PBx p-value
No. of cases (total n=1,598) 73 (4.6) 120 (7.5) 75 (4.7) 212 (13.3) 1,118 (70.0)
Age (y) 65.8±8.6 65.9±8.6 66.2±10.3 64.8±8.0 63.6±8.6 0.025
Hypertension 19 (26.0) 49 (40.8) 17 (22.7) 55 (25.9) 323 (28.9) 0.028
Diabetes mellitus 10 (13.7) 10 (8.3) 9 (12.0) 28 (13.2) 188 (16.8) 0.091
BMI (kg/m2) 24.8±2.8 24.6±2.9 24.8±4.5 24.5±2.8 27.5±83.1 0.018
Biopsy history 20 (27.4) 14 (11.7) 9 (12.0) 15 (7.1) 66 (5.9) <0.001
PSA (ng/mL) 6.2±2.2 5.5±1.7 5.8±1.9 5.8±2.1 5.8±2.1 0.031
PV (cc) 44.2±16.2 41.6±15.0 46.0±25.2 41.9±16.4 41.8±17.0 0.566
PSA density (ng/mL/cc) 0.17±0.10 0.16±0.08 0.16±0.10 0.16±0.09 0.16±0.10 0.857
VPC (cc/core) 2.9±1.3 3.0±1.1 1.9±1.1 3.0±1.2 3.5±1.4 <0.001
Number of total core 15.4±1.8 14.0±0.0 24.0±0.0 14.4±1.6 12.0±0.0 <0.001
Number of positive core 2.6±4.4 1.4±2.5 2.3±4.4 1.5±2.9 0.7±1.9 <0.001
Diagnosis of prostate cancer 32 (43.8) 49 (40.8) 26 (34.7) 70 (33.0) 224 (20.0) <0.001
Gleason score 0.037
   6 9/32 (28.1) 24/49 (49.0) 11/26 (42.3) 24/70 (34.3) 113/224 (50.4)
   ≥7 23/32 (71.9) 25/49 (51.0) 15/26 (57.7) 46/70 (65.7) 111/224 (49.6)
Period <0.001
   2006–2010 0 (0.0) 0 (0.0) 0 (0.0) 62 (29.2) 604 (54.0)
   2011–2015 73 (100.0) 120 (100.0) 75 (100.0) 150 (70.8) 514 (46.0)
Values are presented as number (%) or mean±standard deviation. 
MR-TBx, magnetic resonance imaging targeted biopsy; 12+2HLTBx, 12+2 hypoechoic lesion target biopsy; PBx, prostate biopsy; BMI, body mass 
index; PSA, prostate-cancer specific antigen; PV, prostate volume; VPC, volume per core.
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0.951–0.982; p<0.001), VPC (<3.0 cc/core) (OR, 2.37; 95% CI, 
1.509–3.711; p<0.001), and biopsy methods (p=0.045) were iden-
tified as the significant factors in the multivariate analysis. 
In the biopsy methods, MR-TBx was superior to other pro-
tocols in cancer detection, but it was shown to have no sig-
nificant difference with sPBx (OR, 0.46; 95% CI, 0.240–0.865; 
p=0.016; OR, 0.62; 95% CI, 0.266–1.462; p=0.277; respectively) 
(Table 2).
We also performed a sub-analysis according to the pres-
ence of biopsy history. For patients who underwent initial 
PBx, multivariate analysis reported that age (OR, 1.07; 95% 
CI, 1.048–1.088; p<0.001), PSA (OR, 1.24; 95% CI, 1.143–1.338; 
p<0.001), PV (OR, 0.97; 95% CI, 0.951–0.981; p<0.001), VPC (<3.0 
cc/core) (OR, 2.21; 95% CI, 1.440–3.405; p<0.001), and biopsy 
methods (p=0.007) were the significant predictors (Table 3). 
Among the biopsy methods, sPBx was comparable to MR-
TBx in terms of PCa diagnosis (p=0.478), whereas the other 
protocols have a significantly lower detection rate than MR-
TBx (OR, 0.39; 95% CI, 0.197–0.772; p=0.007).
For patients with a biopsy history, age (OR, 1.11; 95% CI, 
1.036–1.182; p=0.002) and VPC (<3.0 cc/core) (OR, 4.55; 95% CI, 
1.621–12.791; p=0.004) were identified as the significant fac-
tors in the multivariate analysis. Notably, the biopsy meth-
ods were not found as significant factors in repeat biopsy 
(Table 3).
DISCUSSION
Age, PSA, and PV were considered as significant predic-
tors of PCa diagnosis [9]. Among these variables, PSA had 
a major drawback, as it could be possibility affected by its 
lack of cancer specificity and the lack of a common upper 
or lower threshold value [10,11]. Developing a strategy for 
utilizing the clinical parameters that are routinely evalu-
ated, VPC calculated by PV and the number of biopsy cores 
could be beneficial in terms of cost, time, and treatment de-
Table 2. Univariate and multivariate logistic regression analyses predicting the presence of prostate cancer 
Characteristic
Univariate Multivariate
OR (95% CI) p-value OR (95% CI) p-value
Agea 1.05 (1.038-1.069) <0.001 1.07 (1.051-1.094) <0.001
Previous biopsy history 1.30 (0.867-1.940) 0.206
PSAa 1.17 (1.097-1.238) <0.001 1.17 (1.078-1.269) <0.001
PVa 0.96 (0.952-0.969) <0.001 0.97 (0.951-0.982) <0.001
VPC <3.0 cc/core 3.38 (2.644-4.327) <0.001 2.37 (1.509-3.711) <0.001
Biopsy methods <0.001 0.045
   MR-TBx Reference Reference
   Saturation biopsy 0.68 (0.350-1.320) 0.254 0.62 (0.266-1.462) 0.277
   Other protocols 0.40 (0.246-0.640) <0.001 0.46 (0.240-0.865) 0.016
OR, odds ratio; CI, confidence interval; PSA, prostate-cancer specific antigen; PV, prostate volume; VPC, volume per core; MR-TBx, magnetic reso-
nance imaging targeted biopsy.
a:Continuous variables. 
Table 3. Univariate and multivariate logistic regression analyses for predicting the presence of prostate cancer according to biopsy history 
Characteristic
Initial biopsy Repeat biopsy
Univariate Multivariate Univariate Multivariate
OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value
Agea 1.05 (1.037-1.069) <0.001 1.07 (1.048-1.088) <0.001 1.06 (1.004-1.114) 0.035 1.11 (1.036-1.182) 0.002
PSAa 1.19 (1.114-1.266) <0.001 1.24 (1.143-1.338) <0.001 0.97 (0.800-1.168) 0.725
PVa 0.96 (0.950-0.969) <0.001 0.97 (0.951-0.981) <0.001 0.97 (0.939-0.996) 0.027 1.03 (0.939-1.125) 0.547
VPC <3.0 cc/core 3.36 (2.600-4.349) <0.001 2.21 (1.440-3.405) <0.001 3.49 (1.476-8.256) 0.004 4.55 (1.621-12.791) 0.004
Biopsy methods 0.001 0.007 0.025 0.225
   MR-TBx Reference Reference Reference
   Saturation biopsy 0.93 (0.442-1.951) 0.846 0.73 (0.299-1.759) 0.478 0.10 (0.011-0.978) 0.048 0.13 (0.012-1.455) 0.098
   Other protocols 0.47 (0.266-0.822) 0.008 0.39 (0.197-0.772) 0.007 0.29 (0.108-0.788) 0.015 0.50 (0.143-1.731) 0.272
OR, odds ratio; CI, confidence interval; PSA, prostate-cancer specific antigen; PV, prostate volume; VPC, volume per core; MR-TBx, magnetic reso-





cision making. After introducing VPC, several studies have 
investigated the relationship between PV and the number 
of biopsy cores [9,12-14]. Finally, VPC was an even stronger 
independent predictor of biopsy results than PV [9].
A direct relationship showing higher CDR for lower VPC 
supports the idea that adequately sampling the prostate is 
critical in avoiding low CDR. Vashi et al. [12] developed a 
mathematical model to calculate the number of biopsy cores 
that considered age, PV, tumor volume, and doubling time. 
Remzi et al. [13] suggested the Vienna nomogram to deter-
mine the number of cores based on age and PV in patients 
with PSA values of 2 to 10 ng/mL. The increased number of 
biopsy cores was considered to possibly result in greater dis-
comfort and more complications for the patient. Therefore, 
the optimal cut-off value of 4.0 was suggested for high CDR 
without taking an excessive number of biopsy specimens in 
patients with PSA <20 ng/mL [9]. In this study, the cut-off 
value of VPC (3.0 cc/core) was obtained by AUC of the ROC 
curve for patients with PSA <10.0 ng/mL.
MRI before PBx in patients who had undergone an 
initial biopsy improved the diagnostic yield of  clinically 
significant cancer by reducing unnecessary PBx [15]. This 
study also supports the usefulness of prebiopsy MRI by con-
firming the high CDR of MR-TBx in the initial biopsy. The 
American Urological Association consensus statement on the 
recommendation to consider MRI for patients with negative 
results in prior PBx was made to improve CDR [16]. Howev-
er, interestingly, this study reported that biopsy methods at 
repeat biopsy were not identified as significant factors. We 
assumed that this was due to the fact that MRI is only a 
tool used to increase the diagnostic rate of clinically signifi-
cant PCa, not to increase the detection rate of insignificant 
PCa [17]. In particular, mimicking lesion may exist in MRI 
due to chronic prostatitis or other reasons such as previous 
PBx procedure. Therefore, these mimicking lesions may de-
crease the accuracy of diagnosing PCa. We considered that 
biomarkers are useful for discriminating these patients with 
mimicking lesions to appropriately identify patients who 
will undergo PBx. Second, VPC, instead of biopsy methods, 
was identified as a significant factor to predict PCa in pa-
tients with repeat biopsy. Notably, this result does not imply 
that MRI has no efficacy for patients with repeat biopsy, 
but our data indicate that proper core number should be ad-
justed using VPC, especially for cases with barrier to use of 
MRI.
Generally, sPBx is believed to result in higher CDR [18]. 
There was no significant difference in the complications be-
tween sPBx and standard biopsy [19]. In our study, the CDR 
of sPBx is compatible to that MR-TBx. However, since sPBx 
requires more needle stapling, it is not suitable for office use 
considering pain or discomfort [20]. Especially, as the number 
of needles increased, tolerability of patients decreased. Thus, 
sPBx was performed only under general anesthesia, not lo-
cal anesthesia.
This study evaluated the CDRs according to several bi-
opsy methods in patients with PSA <10.0 ng/mL. In general, 
30% to 35% of men with a PSA level of 4 to 10 ng/mL are 
diagnosed with PCa [6]. In this cohort with a median PSA 
of 5.41 ng/mL, the CDR of 25.1% was relatively lower than 
those in the previous studies. For 12-core PBx being the 
standard diagnostic method, the CDR of 20.0% was reported. 
These results could be related to several reasons. First, the 
detection rate in our cohort may differ from those in other 
studies performed by experts. Our institution’s training pro-
gram recommended the policy that most PBx procedures, ex-
cluding MR-TBx, sPBx and 12+HLTBx, should be performed 
by residents. Long periods of observation were required for 
the operator to achieve mastery in skills at a level sufficient 
for independent practice [21,22]. Second, although prebiopsy 
MRI was performed to reduce the number of cases with 
unfortunately missed PCa diagnosis, the MR-TBx protocol in 
our institution utilized the cognitive technique.
In NCCN, if MRI is available, MRI-guided biopsy is rec-
ommended using the MRI/ultrasonography fusion biopsy 
[6]. Nevertheless, this study reaffirmed that CDR of MR-
TBx was higher than those of other PBx methods, which 
are generally used in practice. However, MRI and biomarker 
required additional cost. Furthermore, the costs of MRI and 
biomarkers are not reimbursed by the insurance before PCa 
diagnosis in Korea.
Complications including hematuria, infection, lower 
urinary tract symptoms, and pain occurred after PBx. Hos-
pitalization for the management of serious biopsy-related 
adverse events was required in a minority of patients be-
cause of  massive hematuria (<1%), febrile urinary tract 
infection or sepsis (0%–6.3%), and acute urinary retention 
(0.2%–1.7%), which are related to the increasing number 
of sampling cores [23]. To the best of our knowledge, there 
were no previous studies that have directly compared the 
complication rate among biopsy methods including MR-
TBx, sPBx, extended biopsy, and 12-core PBx In our cohort, 
cancer detection of sPBx was comparable to that of MR-TBx. 
However, MR-TBx showed a higher ratio of the number of 
positive cores to that of the total cores (37.1% vs. 27.5%) and 
proportion of significant cancer (Gleason score ≥7 [3+4]) (71.9% 
vs. 57.7%) than sPBx. Furthermore, considering the direct 
relationship of complications and increasing number of bi-
opsy cores, our findings will help clinicians decide the use of 
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either MR-TBx or sPBx in clinical setting.
This study has some limitations. First, there were no 
obvious criteria for selecting the biopsy methods. Moreover, 
multiple physicians as biopsy operators performed PBx, 
which could account for the heterogeneity in the results. 
However, this demonstrates that an average group of urolo-
gists can achieve good PBx results in clinical practice. Sec-
ond, analysis of the Prostate Imaging Reporting and Data 
System (PI-RADS) and CDR was not applied in this study. 
In patients who underwent biopsy before PI-RADS, MRI 
readings could not be converted back to PI-RADS in this ret-
rospective analysis. Moreover, since the version of PI-RADS 
has changed during the study period, there was a concern 
that the results could be inconsistent. Third, although 
complications and CDR might be the considerable factors 
for choosing the appropriate biopsy method, this study did 
not analyze complications. Nevertheless, to the best of our 
knowledge, this study is the first to compare the various 
methods of PBx simultaneously. 
CONCLUSIONS
This study reaffirmed the efficacy of MR-TBx on CDR 
in real-world practice. In cases with barriers to performing 
MRI, VPC might be useful for adjusting the optimal num-
ber of biopsy cores in repeat biopsy. 
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